Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443261 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00443261 is a Phase 1 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT00443261, a Phase 1 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
Interventions
- DRUG Cisplatin
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443261
The ClinicalTrials.gov registry entry for NCT00443261 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT00443261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00443261 about?
NCT00443261 is a clinical study titled "Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
What is the current status of trial NCT00443261?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-02. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00443261?
The interventions under investigation include: Cisplatin (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00443261?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.